DBP International: Positive opinion in international phase (PCT) of patent application for iron succinate
Double Bond Pharmaceutical International AB (publ) (“DBP”) is pleased to announce a positive written opinion regarding their international patent application relating to iron succinate (Inofer) for treatment of patients diagnosed with heart failure with reduced ejection fraction (HFrEF). The application enters the national phase in May 2022.
The results of clinical trials undertaken by DBP indicate that ferrous succinate (“Inofer”) markedly and significantly improved iron uptake, iron saturation, and iron stores in patients with heart failure and iron deficiency.
Inofer is a low-cost oral alternative to a widely sold product called FerInject (which is, as its name indicates, administered intravenously). In 2020, FerInject reported global net sales of US$550 million.
More about the clinical study of Iron Succinate:
https://mb.cision.com/Main/12720/2974295/1151389.pdf,
https://www.scirp.org/journal/paperinformation.aspx?paperid=106484
More about the patent application of Iron Succinate: